Latest news with #OCV
Hans India
22-05-2025
- Health
- Hans India
Bharat Biotech's oral cholera vax clears phase-3 trials: Study
Hyderabad: Bharat Biotech, which has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 19 vaccines, 4 biotherapeutics, has made a significant announcement. Its oral cholera vaccine (OCV) Hillchol has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV. The above study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomized phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol® in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India. The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety. Key highlights from the findings are as follows: Robust Immunogenicity: Hillchol® demonstrated a greater than 4-fold rise in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, proving non-inferiority to licensed vaccines; and, Strong Safety Profile: Adverse events were mild and comparable between the two vaccines. Broad Age Coverage: The vaccine was well-tolerated and immunogenic across all age groups—including infants (≥1 year), children, and adults. 'This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,' said Dr Krishna Ella, Executive Chairman, Bharat Biotech. Dr Ella added, 'Cholera is a vaccine-preventable disease that has faced a surge in outbreaks along with a huge shortage of vaccines. The new generation Oral Cholera Vaccine Hillchol®, featuring a simplified single stable O1 Hikojima strain, inducing robust antibodies against both Ogawa and Inaba serotypes, aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.' As cholera continues to threaten communities lacking clean water and sanitation, Hillcholprovides a streamlined, scalable solution designed to support global health programmes and ensure equitable access to life-saving demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol.
The Hindu
21-05-2025
- Health
- The Hindu
Phase III clinical trials of Bharat Biotech's oral cholera vaccine over
Vaccine maker Bharat Biotech on Wednesday said its oral cholera vaccine Hillchol has successfully completed phase III clinical trials. The double-blind, randomised phase III clinical trial was to evaluate safety, immunogenicity, non-inferiority and lot-to-lot consistency of single component of the OCV in comparison to a comparator vaccine (Shanchol) in a participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India. The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. Secondary endpoints included Geometric Mean Titre (GMT) measurements and safety. 'Hillchol demonstrated a greater than 4-fold rise in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, proving non-inferiority to licensed vaccines... supporting its potential as an effective OCV,' Bharat Biotech said in a release on the study findings published in the Vaccine journal ScienceDirect. Paves way for distribution Adverse events were mild and comparable between the two vaccines. The vaccine was well-tolerated and immunogenic across all age groups — including infants, children, and adults. The trials pave the way for distribution of Hillchol within the next few months, it said. 'The publication [of the study] reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials and reliable clinical data. It highlights our continued commitment to providing affordable, effective and accessible vaccines for the populations who need them the most,' Executive Chairman Krishna Ella said. Cholera is a vaccine-preventable disease that faced a surge in outbreaks along with a huge shortage of vaccines. Hillchol features a simplified single stable O1 Hikojima strain. It aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats, he said. Global demand for OCVs is close to 100 million doses a year. Given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol, the company said. BBV131 - trade name Hillchol – has received market authorisation in India.
Yahoo
25-02-2025
- Yahoo
Stay informed: Crawford County Sheriff's new app connects instantly
The Crawford County Sheriff's Office launched a new smartphone app to better connect with residents and visitors. The app, developed by provides quick access to public information and is designed to be user-friendly, according to an announcement from the Sheriff's Office. Users will receive push notifications about weather alerts, road closures and other warnings. In a few clicks, users can access features such as contact information, jail and inmate details, sex offender lists, cyber safety tips, mental health resources and more. The app also allows users to submit tips and explore employment opportunities with the Sheriff's Office. 'Over 80% of people in the United States own and use smartphones as their primary means of communication,' Kevin Cummings, OCV partner and CRO, said. 'Mobile apps offer agencies a better way to alert, inform and prepare the public. Apps allow public safety agencies the ability to reach and serve their citizens where they are: their smartphones.' The app is available for free download at the App Store and Google Play. Users can find it by searching for "Crawford County Sheriff, OH." The app aims to enhance communication and provide essential information to the community more efficiently, according to the announcement. This story was created by Jane Imbody, jimbody@ with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the information gathering, review, editing and publishing process. Learn more at This article originally appeared on Bucyrus Telegraph-Forum: Crawford County Sheriff's Office launches new smartphone app
BBC News
14-02-2025
- Health
- BBC News
Tins to know as Ghana begin cholera vaccination afta 50 pipo die across di kontri
Di Ghana health service don begin to vaccinate pipo against cholera for di kontri afta ova 50 pipo don die. So far at least five out of di kontris 16 regions of Ghana don confam cases of cholera as hospitals dey struggle to deal wit di outbreak. Many oda pipio bin dey on admission. Data from di health service and ministry of health don show say for di greater Accra, Eastern, Central, Ashanti and Western regions na di regions wey don record cases. Dr Denis Laryea wia be oga in charge of disease surveillance don tok say "pipo bin dey die sake of many pipo wia get di disease try to self-medicate, wia odas bin dey report to di hospital three to four days afta di infection." Na so dem begin to vaccinate pipo for di greater Accra region between 14 -17 February 2025 as im be di region wit di most cases - more than 200 out of di 6,000 cases across di kontri. Di western and central regions also gat plenty cases. For three days, di Ghana health service say dem dey target 300,000 pipo for dis vaccination for Accra. Di areas for dis vaccination na di Ablekuma south, Okaikwei south and ashiedu keteke, all for di greater Accra region. Who qualify for dis vaccination Di health service say di oral cholera vaccine (OCV) na for every body wey be one year and above. Dem also tok say di vaccine dey safe and effective "Make una look for your area for di vaccination team, and take di vaccine to protect yourserf," di health service tok. Di world health organisation don tok say cholera na "highly contagious illness wia be global health threat. If dem no treat am, cholera fit to lead to death," country director for di WHO Frank Lule tok. For dis round of vaccination, di GHS say dem go do house-to-house and target districts wey be hotspots. Symptoms of cholera Di Ministry of health bin dey educate pipo since last year ova di illness. Dem tok say to know say di sickness una dey see na cholera, di patient go get - diarrhoea (wen pipo go dey poopoo water water) - Vomitting - Patients go dey thirsty, tired and weak - Loss of body fluids wia fit lead to death Cholera dey spread by flies, water and food. E dey transfer from faecal matter to pesin mouth. If pesin drink water and food wey contaminate, im fit sick of cholera How to prevent cholera According to di health service - pipo gat to drink clean water - Wash your hands with soap and running water - Wash fruits and vegetables well well - Practise good hygiene - Eat food wey hot - Make pipo stop open defecation - If pesin get acute diarrhoea dem gat to drink ORS quick and visit di hospital - Pipo wia dey sell food gat to wash plates, cups, and oda tins well well
